A rare case of fatal hepatic veno-occlusive disease and rupture of the spleen vein and artery after Gemtuzumab Ozogamicin (Mylotarg®) infusion Doença veno-oclusiva fatal por Gentuzumab Ozogamicin

A rare case of fatal hepatic veno-occlusive disease and rupture of the spleen vein and artery after Gemtuzumab Ozogamicin (Mylotarg®) infusion Doença veno-oclusiva fatal por Gentuzumab Ozogamicin

Gemtuzumab Ozogamicin (Mylotarg®) targets leukemia cells expressing the CD 33 receptor by means of a monoclonal antibody conjugated to a cytotoxic agent, calicheamicin. It was approved for use in elderly patients with relapsed or refractory acute myeloid leukemia and reversible hepatotoxicity is com...

Full description

Bibliographic Details
Main Authors: Celso M. Massumoto, Ronald F. Pinheiro, Edilson D. Pinheiro Júnior, Otávio C. Baiocchi, Adelson Alves
Format: Article
Language:English
Published: Elsevier 2004-01-01
Series:Revista Brasileira de Hematologia e Hemoterapia
Subjects:
Gentuzumab Ozogamicina
doença hepática veno-oclusiva
vasos hepáticos
Gemtuzumab Ozogamicin
Hepatic veno-occlusive disease
spleen vases
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842004000300013

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842004000300013

Similar Items